Skip to navigation Skip to content

Clinical Trial: Cognitive Processing Speed Changes in Relapsing MS Treated With Ozanimod (RPC-1063)

Share

Details
Type of MS: RRMS|SPMS
Treatment mode of action: To improve cognition
Number of Subjects: 250
Medication: Ozanimod
Location: Colorado
Institutions: Advanced Neurology of CO/Advanced Neurosciences Research
2121 East Harmony Road Suite 180 Fort Collins CO 80528
  Contact Information
Kelley Sage
970-237-9141
kelleys.advancedneurology@gmail.com

Funding:

Celgene

Description

A study to determine if oral ozanimod can affect cognitive processing speed in people with relapsing MS. All subjects will receive orally administered ozanimod HCl 1 mg. 

Share


© 2022 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.